Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol thymosin alpha1
- Development stage
- Phase 3
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Peptides, Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
**Polyethylene glycol thymosin alpha1 (PEG-Tα1)** is a pegylated conjugate of thymosin alpha1, a 28-amino acid synthetic peptide derived from the thymus gland, designed as a long-acting immunomodulator to extend the half-life and pharmacokinetics of the parent peptide. It enhances immune function by stimulating dendritic cell maturation, promoting cytokine production such as IL-12, increasing T-cell proliferation and differentiation, restoring lymphokine-activated killer cell activity, and augmenting antigen presentation via Toll-like receptor signaling. Primarily investigated in combination with antivirals like adefovir for chronic hepatitis B, PEG-Tα1 has demonstrated efficacy in improving viral response rates and safety in phase III trials, positioning it as a category 1.1 chemical drug in certain regulatory contexts, with potential broader applications in viral infections due to its tolerability and immune-enhancing profile.[1][2][14]
- Other names
- Polyethylene Glycol thymosin alpha1
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TLR (Toll-like receptors)
Beyond the preview
Go deeper on polyethylene glycol thymosin alpha1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol thymosin alpha1.